摘要
果糖-1,6-二磷酸酶(fructose-1,6-bisphosphatase,FBPase)是肝葡萄糖异生路径中的一个限速酶,催化果糖-1,6-二磷酸水解为果糖-6-磷酸。抑制FBPase的活性,可减少内源性葡萄糖的生成,降低血糖水平,FBPase抑制剂是潜在的新型治疗Ⅱ型糖尿病的药物。本文综述了近年来FBPase一磷酸腺苷(adenosine monophosphate,AMP)变构抑制剂研究的最新进展。
Fructose-1,6-bisphosphatase（FBPase）,a rate-limiting enzyme involved in the pathway of gluconeogenesis,can catalyze the hydrolysis of fructose-1,6-bisphosphate to fructose-6-phosphate.Upon inhibiting the activity of FBPase,the production of endogenous glucose can be decreased and the level of blood glucose lowered.Therefore,inhibitors of FBPase are expected to be novel potential therapeutics for the treatment of type II diabetes.Recent research efforts were reviewed in the field of developing allosteric inhibitors interacting with the AMP binding site of FBPase.
出处
《药学学报》
CAS
CSCD
北大核心
2011年第11期1291-1300,共10页
Acta Pharmaceutica Sinica
